« Home « Kết quả tìm kiếm

Response evaluation criteria in solid tumors

Tìm thấy 13+ kết quả cho từ khóa "Response evaluation criteria in solid tumors"

Assessment of various efficacy outcomes using ERIVANCE-like criteria in patients with locally advanced basal cell carcinoma receiving sonidegib: Results from a preplanned sensitivity analysis

tailieu.vn

Vismodegib is approved in the US for the treatment of adults with mBCC or laBCC that has recurred after surgery, or for those who are not surgical or radiotherapy candidates, and is approved in the EU, Switzerland, and Australia for adults with laBCC or mBCC when surgery or radiotherapy is inappropriate . Tumor assessments for pa- tients with laBCC were performed by a central review committee and investigators using modified Response Evaluation Criteria in Solid Tumors (mRECIST).

Tumor response as defined by iRECIST in gastrointestinal malignancies treated with PD-1 and PD-L1 inhibitors and correlation with survival

tailieu.vn

Tumor diameter changes as defined by immunotherapy Response Evaluation Criteria in Solid Tumors (iRECIST) were studied to determine treatment response and association with OS.. Results: Based on the best overall response, the tumor diameter ranged from − 100 to + 135.3% (median. Using univariate analysis, patients with a tumor diameter maintaining a <. In multivariable analysis, patients with a tumor diameter with a <. Conclusions: Tumor diameter with a <.

Evaluating the effect of Neoadjuvant chemotherapy for esophageal Cancer using the RECIST system with shorter-axis measurements: A retrospective multicenter study

tailieu.vn

The Response Evaluation Criteria in Solid Tumors system, which employs the longest diameter for measuring tumors, is commonly used for evaluating treatment effects. Thus, we evaluated this issue by measuring not only the longest diameter but also the shorter axis of the tumor.. The longest and shortest tumor diameters were measured in each case.

Correlation between immune-related adverse events and therapeutic efects of nivolumab in patients with malignant pleural mesothelioma

tailieu.vn

Adverse events were assessed according to the National Cancer Institute-Common Toxicity Criteria for Adverse Events (NCI-CTCAE) version 5.0. Clinical responses to the treatment were categorized as either complete response (CR), partial response (PR), sta- ble disease (SD), or progressive disease (PD) according to the modified Response Evaluation Criteria in Solid Tumors (mRECIST) or the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.

Key actors in cancer therapy: Epigenetic modifiers

tailieu.vn

It has been shown that belinostat inhibited growth of prostate cancer cells in vitro, and reduced metastasis in vivo (Qian et al., 2008).. it was reported that “no RECIST (Response Evaluation Criteria in Solid Tumors) major responses have been seen” (Sherman et al., 2013). of the head and neck (Haigentz Jr et al., 2012). Chen et al., 2006. Catalano et al., 2007. Cipro et al., 2012. Aztopal et al., 2018b).

Chapter 077. Approach to the Patient with Cancer (Part 5)

tailieu.vn

A complete response is defined as disappearance of all evidence of disease, and a partial response as >50% reduction in the sum of the products of the perpendicular diameters of all measurable lesions. The determination of partial response may also be based on a 30% decrease in the sums of the longest diameters of lesions (Response Evaluation Criteria in Solid Tumors, or RECIST, criteria).

Pyrotinib combined with thalidomide in advanced non-small-cell lung cancer patients harboring HER2 exon 20 insertions (PRIDE): Protocol of an open-label, singlearm phase II trial

tailieu.vn

Dose adjustment, interruption, or discontinuation of study drug according to the adverse events (AEs) is detailed in Table 2.. response will be assessed according to the Response Evaluation Criteria In Solid Tumors, version 1.1 [27].. AEs during the treatment period and within 28 days after the last dose will be recorded and graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0.

A phase I/II clinical trial on the efficacy and safety of NKT cells combined with gefitinib for advanced EGFR-mutated non-small-cell lung cancer

tailieu.vn

Table 1 Treatment schedule for the frequency of gefitinib and NKT cell in both arms of the trail Week-4-. detection, according to the Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST Version 1.1), com- puted tomography (CT) will be used to measure the size of solid tumours during screening, treatment and follow- up in the study. All baseline assessments of the tumour focus size should be completed as close to the start of treatment as possible.

Nanoparticle albumin-bound paclitaxel and PD-1 inhibitor (sintilimab) combination therapy for soft tissue sarcoma: A retrospective study

tailieu.vn

The patient eligibility criteria included: 1) histologically proven STS, 2) treatment with nab-paclitaxel plus PD-1 inhibitor, 3) locally unresectable or multiple metastases, 4) measurable lesions accord- ing to the response evaluation criteria in solid tumors (RECIST. The patients received 300 mg/m 2 of nab-paclitaxel (Hen- grui Pharmaceutical, Lianyungang, China) and 200 mg of PD-1 inhibitor (sintilimab.

Evaluating the impact of 18F-FDG-PET-CT on risk stratification and treatment adaptation for patients with muscleinvasive bladder cancer (EFFORT-MIBC): A phase II prospective trial

tailieu.vn

Patients will be followed up until death or disease progression defined as per: Response Evaluation Criteria in Solid Tumors. Once disease progression has been confirmed, survival status will be assessed 3- monthly until death, withdrawal of consent or the end of the study, whichever occurs first.

Xạ trị lập thể định vị thân ở bệnh nhân ung thư phổi không tế bào nhỏ giai đoạn I với u phổi ngoại vi

tailieu.vn

Đánh giá đáp ứng sau điều trị theo tiêu chuẩn đánh giá đáp ứng của các khối u đặc với điều trị - RECIST 1.1 (Response Evaluation Criteria in Solid Tumors).. Tại thời điểm 3 tháng được đánh giá thêm bằng tiêu chuẩn PET đánh giá đáp ứng chuyển hóa của các khối u với điều trị PERCIST 1.0 (PET Response Criteria in Solid Tumors). Đánh giá tác dụng phụ của điều trị theo Tiêu chuẩn của Viện ung thư quốc gia Mỹ (National Cancer Institute Common Terminology Criteria or Adverse Events – CTCAE).

Khóa luận tốt nghiệp Đại học ngành Dược học: Khảo sát tình hình sử dụng vinorelbine trong điều trị ung thư phổi không tế bào nhỏ tại Trung tâm y học hạt nhân và ung bướu - Bệnh viện Bạch Mai

tailieu.vn

Theo tiêu chuẩn đánh giá đáp ứng khối u đặc RECIST (Response Evaluation Criteria in Solid Tumors) bệnh nhân UTPKTBN đƣợc điều trị bằng hóa chất vinorelbine trong suốt thời gian nghiên cứu có tỷ lệ đáp ứng điều trị đƣợc trình bày trong hình 3.3:. 34 bệnh nhân ổn định (46,6. 12 bệnh nhân bệnh tiến triển (16,4%).. Tỷ lệ bệnh nhân có chỉ số CEA giảm trong cả quá trình điều trị là 21,4%, Cysfra 21-1 là 18,5%..

Nghiên cứu kết quả điều trị bằng xạ trị lập thể định vị thân cyberknife ở bệnh nhân ung thư phổi giai đoạn sớm

tailieu.vn

Đánh giá đáp ứng sau điều trị theo tiêu chuẩn đánh giá đáp ứng các khối u với điều trị RECIST 1.1 (Response Evaluation Criteria in Solid Tumors) sau 3 - 6 tháng [10].. Đánh giá tác dụng phụ của điều trị theo tiêu chuẩn của Viện Ung thư Quốc. Theo dõi BN sau điều trị: BN được theo dõi vào thời điểm 3, 6 tháng sau điều trị, sau đó định kỳ mỗi 6 tháng (khám lâm sàng, chụp CT lồng ngực, PET/CT (sau 3 - 6 tháng).. Sử dụng student t-test so sánh các giá trị trung bình, Chi-square test so sánh tỷ lệ.

A Phase 2a cohort expansion study to assess the safety, tolerability, and preliminary efficacy of CXD101 in patients with advanced solid-organ cancer expressing HR23B or lymphoma

tailieu.vn

The primary end point of the expansion component of the study was assessment of the safety. and toxicity of the RP2D. with a meas- urable advanced malignant tumour [criteria of Cheson et al for patients with lymphoma and Re- sponse Evaluation Criteria In Solid Tumors [RECIST;. version 1.1] [22] for patients with solid organ malignan- cies. In the expansion cohort patients with solid-organ can- cers only were required to have high tumour expression of the HR23B by immunohistochemistry (IHC).

Hepatocellular Carcinoma: Targeted Therapy and Multidisciplinary P39

tailieu.vn

Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).. Benatsou B, Lassau N, Chami L, Koscielny S, Roche A, Ducreux M et al (2008) Dynamic contrast-enhanced ultrasonography (DCE-US) with quantification for the early evaluation of hepato cellular carcinoma treated by bevacizumab in phase II. J Clin Oncol 26(Suppl):4588 [Abstract].

Intraarterial contrast-enhanced ultrasound to predict the short-term tumour response of hepatocellular carcinoma to Transarterial chemoembolization with Lipiodol

tailieu.vn

Contrast-enhanced MRI can be performed 1–3 months after TACE to assess the tumour response (TR) based on the modified Response Evaluation Criteria in Solid Tumours (mRECIST) guide- lines [4–6].. The significance of the intraprocedural evaluation and prediction of TR lies in their ability to help to determine the end-point of TACE, and thus help determine future treatment and predict prognosis, which is beneficial to patients [7, 8].

Prospective comparison of early interim 18F-FDG-PET with 18F-FLT-PET for predicting treatment response and survival in metastatic breast cancer

tailieu.vn

To facilitate a direct comparison, we used the Euro- pean Organization for Research and Treatment of Can- cer (EORTC) criteria and PET Response Criteria in Solid Tumors (PERCIST) to evaluate the metabolic re- sponse in both 18 F-FDG-PET and 18 F-FLT-PET.

Evaluation of IL-2 and Dexamethasone intracavitary injection on the management of malignant efusion in children with solid tumors or lymphoma

tailieu.vn

All patients in the control group were treated according to pathology diagnosis without IL-2 therapy.. Among them, 40 patients with solid tumors and 66 patients with lym- phoma were further diagnosed with pleural effusion, ascites, or pericardial effusion.

Pre-existing interstitial lung disease is associated with onset of nivolumabinduced pneumonitis in patients with solid tumors: A retrospective analysis

tailieu.vn

Pre-existing interstitial lung disease is associated with onset of nivolumab-. induced pneumonitis in patients with solid tumors: a retrospective analysis. The aim of this study was to examine the association between pre-existing interstitial lung disease (ILD) on chest computed tomography (CT) and nivolumab-induced pneumonitis among different types of solid tumors.. We collected baseline patient characteristics and assessed pre-existing ILD on baseline chest CT..

Clinical characteristics and risk factors associated with Pneumocystis jirovecii infection in patients with solid tumors: Study of thirteen-year medical records of a large cancer center

tailieu.vn

factors associated with Pneumocystis jirovecii infection in patients with solid tumors: study of thirteen-year medical records of a large cancer center. Background: Pneumocystis jirovecii pneumonia (PCP)-related risk factors among patients with solid tumors are not completely defined. Methods: We retrospectively reviewed the medical records of patients with solid tumors diagnosed with PCP between 2006 and 2018 at a cancer center in Tokyo, Japan.